Delanzomib

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameDelanzomib
Drug Alias Name德兰佐米Delanzomibum迪兰佐米E/CEP-18770NPH-007098 +[10] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionProteasome inhibitorsApoptosis stimulants
TargetsProteasome
Therapy Area/IndicationsSolid tumoursMultiple MyelomaLymphoma, Non-Hodgkin
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesNew ZealandItaly +[4] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesTevaCti Biopharma Corp
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesTeva Branded Pharmaceutical Products R&D IncEthical Oncology ScienceCephalon
Active IndicationsN/A
Inactive IndicationsSolid tumoursMultiple MyelomaLymphoma, Non-Hodgkin

Other Information

ATC CodeN/A
Related LinksKEGG